Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

Exclusion Criteria

• •History of certain types of cancer
• •Diagnosis of ulcerative colitis
• •Pregnant female or breast feeding subjects
• •Known obstructive strictures
• •Surgical bowel resection in the past 6 months
• •History of listeria, human immunodeficiency virus (HIV), central nervous system demyelinating disease or untreated TB (tuberculosis)
• •History of poorly controlled medical conditions
• •Specific doses and durations of Crohn's medications
• •Subjects that have previously used infliximab and have never clinically responded unless primary non-response was due to a treatment limiting reaction to infliximab